Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMEL-1: Decitabine plus low-dose melphalan in refractory higher-risk MDS
ChiCTR2500115432Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and melphalan in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Response (CR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
decitabinemelphalan
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500115432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115432.